MOLEKUL / PEPTIDE BIOREGULATION

Tissue extracts and synthetic peptides

Explore organ-derived extracts and synthetic peptides by tissue, with links to composition studies and clinical results.

Findings from selected studies

  • Pain-free walking distance

    In a randomized study of 108 patients with arterial disease, pain-free walking distance rose 46.2% and 31.4% in the two Slavinorm groups and 6.5% with placebo.

For research and education. Seek a qualified healthcare professional for any condition or health concern. Historical research and proposed tissue targets are not treatment recommendations.

Pineamin, retinal, prostate and kidney research update ↗

TISSUE → COMPLEX → SHORT PEPTIDE

Bioregulator research by tissue

Compare the composition of tissue extracts with studies of individual synthetic peptides. Clinical results apply to the preparation used in each study.

Organ-derived extracts and synthetic peptides
Tissue / recordsParent preparation → peptideMolecular linkHuman research & unresolved gap
Cartilage & bonePCC ↗ · Cartalax ↗Cartilage polypeptide complex (PCC)

Cartalax / AED
The 2020 UHPLC–MS paper reports AED in cartilage complex. The 2023 review describes PCC as a mixture spanning 75–846 Da.Source record ↗Source record ↗Cartalax: a published 2015 human dental-surgery study reports better jaw-bone healing; a later research lecture gives 53 patients (28/25). A separate 29-patient knee comparison appears in patent RU2299741C1. PCC Phase II is review-reported and concerns a different preparation.The PCC trial identifier, formulation, protocol and results remain uncertain. The patent reports symptom changes without a significant radiographic change. Cartilage regeneration remains unestablished.
BrainCortexin ↗ · Pinealon ↗ · Cortagen ↗Cortexin / brain polypeptide preparations

Pinealon / EDR; separate Cortagen research
The 2020 analytical paper detects EDR in brain complex. The broader neuropeptide literature discusses Cortexin and short peptides; molecular detection alone does not equate preparations.Source record ↗Source record ↗Cortexin has condition-specific clinical reports and ESCORT. Its stroke evidence needs the independent Cochrane assessment alongside positive original reports.The clinical findings concern Cortexin. Pinealon and Cortagen have their own evidence. Cortagen’s direct parent-product characterization and additional primary studies remain recovery targets.
Pineal glandEpithalamin ↗ · Epitalon ↗ · Pineamin ↗Epithalamin

Epitalon / AEDG
The 2017 analytical study detected AEDG in pineal polypeptide complex, after its earlier design from amino-acid composition.Source record ↗Source record ↗Epithalamin aging cohorts and Pineamin menopause/reproductive studies concern distinct extracts. Pineamin has separate studies of sleep, semen and ovarian-reserve reports.The extract and synthetic AEDG are distinct preparations. Unresolved cohort overlap and limited information about methods restrict interpretation of the longevity findings.
ThymusThymalin ↗ · Thymogen ↗ · Vilon ↗Thymalin

Thymogen / EW; Vilon / KE
The 2021 composition paper identifies KE and EDP in Thymalin and cites prior detection of EW. It distinguishes peptide design from subsequent molecular detection.Source record ↗Source record ↗The 2013 review covers Thymalin, Thymogen and Vilon, but its original trials require separate appraisal. The 266-person aging report concerns the extracts Thymalin and Epithalamin.Avoid assigning extract outcomes to individual peptides. Vilon cell-culture findings are mechanistic, not evidence of human rejuvenation.
Blood vesselsVasolin / Slavinorm ↗ · Vesugen ↗ · KED ↗Vasolin / Slavinorm

Vesugen / KED
KED was detected in vessel complex in the 2020 composition paper. Vesugen is the KED short-peptide entry; the separate KED route preserves sequence-based research navigation.Source record ↗Source record ↗Original vessel-complex records now include 108-person arterial and 190-person venous randomized trials plus separate comparisons. These do not isolate Vesugen or purified KED.Some randomized-study abstracts omit the preparation name. A shared peptide sequence does not establish clinical equivalence between complex preparations and purified KED.
LiverVentvil ↗ · Livagen ↗Ventvil

Livagen / KEDA
The 2020 Russian review discusses the liver complex and defined tetrapeptide together as separate experimental interventions.Source record ↗The recovered review describes animal and cell models of fibrosis/hepatitis, not a human treatment trial.Original model-specific papers and molecular characterization remain necessary. A shared research program is not proof of identical composition or effects.
HeartCardiogen ↗Heart polypeptide complex (review-described)

Cardiogen / AEDR
The cardiovascular review reports detection of AEDR in heart complex. Its original analytical source has not been independently recovered here.Source record ↗Source record ↗The highlighted myocardial-infarction result is preclinical and traces to US7662789B2, cited by the review.The available findings come from patent records. Cardiovascular outcomes in people remain unverified.
ProstateProstatilen ↗ · Prostamax ↗ · Prostateks ↗Prostatilen

Prostamax (adjacent short-peptide program)
Tissue-level research association only in this collection; direct molecular derivation of Prostamax from the clinical Prostatilen formulation has not been established.Source record ↗Source record ↗Historical Prostatilen reports, a 127-patient Prostateks postoperative comparison and a separate 94-patient Prostateks prostatitis comparison are linked with distinct preparation identities.The cited cohorts received Prostatilen. The uncontrolled results leave the treatment effect uncertain.
RetinaRetinalamin ↗ · Normophthal ↗Retinalamin

Normophthal (adjacent short-peptide program)
Shared tissue theme, not a verified product-to-sequence derivation in this collection.Source record ↗Source record ↗Randomized glaucoma reports, a 2025 prospective cohort and an active-route comparison are available. Visual acuity and several between-group outcomes were unchanged.Assess blinding, baseline imbalance, correlated eyes and study overlap. The negative rabbit photochemical-injury experiment is included alongside favorable reports.
Bronchial mucosaChonluten ↗ · Bronchogen ↗Bronchial-mucosa polypeptide complex

Chonluten / EDG; Bronchogen / AEDL
The 2020 UHPLC–MS report identifies EDG and AEDL in bronchial-mucosa complex.Source record ↗Source record ↗A Chonluten institute product report is now linked in the evidence map; its formulation is not independently characterized. The original 2014 Bronchogen report includes 58 adjunctive oral-capsule patients and 20 standard-care controls, with clinical lung-volume measurements.The original experiments and clinical protocols leave uncertainty about sequence-specific effects, respiratory outcomes and occupational exposure.
PancreasPancragen ↗Pancreatic polypeptide complex

Pancragen / KEDW
The 2020 composition paper reports KEDW in pancreatic complex.Source record ↗Source record ↗The evidence map now links a 2011 Pancragen human report, alongside separate primate and cell studies. Thirty healthy comparison subjects are not automatically randomized treatment controls.Full clinical methods, treatment allocation and preparation details still need appraisal before interpreting metabolic outcomes.
Testicular research targetTestagen ↗Parent preparation unknown

Testagen
The 2013 short-peptide catalogue is the traceable source retained for this entry.Source record ↗No additional compound-specific primary clinical report was recovered in the Cartalax update.The research target is not a demonstrated treatment indication. Original identity, composition and clinical sources remain explicit gaps.
KidneyNephropept ↗ · Pielotax ↗Nephropept / separately formulated Pielotax

AED, EDL and AEDG are related experimental sequences
A common tissue target does not establish identical extracts or prove that these sequences were isolated from Nephropept.Source record ↗Source record ↗Pielotax has a historical institute report. The Nephropept Phase II registry reproduction lists a planned 210-person CKD study without numerical outcomes.The source leaves the protocol, actual enrollment, clinical results and preparation characteristics uncertain.

Three distinctions that change the reading.

Detected is different from designed.

The 2017 pineal and 2020 multi-organ papers provide analytical evidence for particular sequences. Other relationships remain review-reported or tissue-level associations.

A patent is its own source type.

The AED patent describes a small human comparison. The Cardiogen infarction claim traces to another patent. Both records link to the original patent and describe the limits of its evidence.

Reviews do not multiply trials.

Later reviews often cite the same early studies. Cortexin’s independent Cochrane assessment appears alongside its original clinical reports; neither review citations nor follow-up papers are independent replications.

Russian historical review ↗ · Multi-organ composition paper / PDF ↗ · Independent stroke evidence assessment ↗

What remains open.

The PCC trial registration and outcomes, original molecular characterization behind some parent–peptide claims, and compound-specific clinical reports for catalogue-only entries remain explicit recovery targets. This collection does not claim an exhaustive bibliography or a completed systematic review.

Explore bibliography & PDFs ↗